Literature DB >> 7595363

Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR.

B Daniel1, G Mukherjee, L Seshadri, E Vallikad, S Krishna.   

Abstract

Using a PCR strategy which detects disruptions in the E2 reading frame we have analysed the progression of human papillomavirus type 16 (HPV-16)-positive cervical lesions. From a total of 192 samples analysed, we detected HPV-16 in 74. In samples from the spectrum of inflammatory states and cervical intraepithelial neoplasia (CIN) grade I lesions we detected episomal forms of the virus. In invasive tumours and in samples from CIN III lesions there were no episomes detected, suggesting that lesions with integrated HPV-16 precede the invasive stage. The RT-PCR analysis demonstrated the presence of E6 transcripts at all stages and E2 transcripts in all early lesions. The E2 transcripts were not detected in 26 out of 29 CIN III lesions and tumours in which there was a disruption in the E2 gene. In tumours with E2 gene disruptions, we used single-primer PCR to demonstrate the presence of E2 gene sequences.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595363     DOI: 10.1099/0022-1317-76-10-2589

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia.

Authors:  Tolga Turan; Mina Kalantari; Kate Cuschieri; Heather A Cubie; Hanne Skomedal; Hans-Ulrich Bernard
Journal:  Virology       Date:  2006-12-18       Impact factor: 3.616

2.  Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.

Authors:  W Stünkel; Z Huang; S H Tan; M J O'Connor; H U Bernard
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  The integration of HPV-18 DNA in cervical carcinoma.

Authors:  S A Corden; L J Sant-Cassia; A J Easton; A G Morris
Journal:  Mol Pathol       Date:  1999-10

4.  Use of multiple displacement amplification in the investigation of human papillomavirus physical status.

Authors:  Mark Francis Evans; Christine Stewart-Crawford Adamson; Genevieve Montagu von Walstrom; Kumarasen Cooper
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

5.  Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China.

Authors:  Wei Wang; Zhengrong Sun; Jianhua Liu; Guili Wang; Zhitao Lu; Weiqiang Zhou; Te Qi; Qiang Ruan
Journal:  Oncol Lett       Date:  2017-03-24       Impact factor: 2.967

Review 6.  Genomic landscape of human papillomavirus-associated cancers.

Authors:  Maria Rusan; Yvonne Y Li; Peter S Hammerman
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

7.  The characteristics of human papillomavirus DNA in head and neck cancers and papillomas.

Authors:  T Major; K Szarka; I Sziklai; L Gergely; J Czeglédy
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

8.  Study of viral integration of HPV-16 in young patients with LSIL.

Authors:  G Gallo; M Bibbo; L Bagella; A Zamparelli; F Sanseverino; M R Giovagnoli; A Vecchione; A Giordano
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

9.  Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR.

Authors:  Krzysztof Lukaszuk; Joanna Liss; Izabela Wozniak; Janusz Emerich; Czesław Wójcikowski
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  HPV16 E2-mediated potentiation of NF-κB activation induced by TNF-α involves parallel activation of STAT3 with a reduction in E2-induced apoptosis.

Authors:  Devan Prabhavathy; Bandaru Niranjana Prabhakar; Devarajan Karunagaran
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.